| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Attention Deficit Disorder with Hyperactivity | 53 | 2013 | 167 | 6.870 |
Why?
|
| Medicaid | 6 | 2025 | 335 | 1.930 |
Why?
|
| Genome-Wide Association Study | 14 | 2018 | 324 | 1.650 |
Why?
|
| Bipolar Disorder | 14 | 2009 | 254 | 1.650 |
Why?
|
| Central Nervous System Stimulants | 9 | 2013 | 63 | 1.450 |
Why?
|
| Methylphenidate | 9 | 2013 | 18 | 1.450 |
Why?
|
| Managed Care Programs | 3 | 2025 | 93 | 1.240 |
Why?
|
| Child | 47 | 2025 | 4306 | 1.180 |
Why?
|
| Accountable Care Organizations | 3 | 2025 | 57 | 1.180 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 7 | 2011 | 32 | 0.930 |
Why?
|
| Primary Health Care | 3 | 2025 | 647 | 0.890 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 93 | 0.830 |
Why?
|
| Adolescent | 39 | 2025 | 5932 | 0.830 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2018 | 675 | 0.760 |
Why?
|
| MicroRNAs | 6 | 2018 | 618 | 0.740 |
Why?
|
| RNA, Small Nucleolar | 3 | 2017 | 7 | 0.730 |
Why?
|
| Medicare Part C | 1 | 2021 | 15 | 0.720 |
Why?
|
| Mental Disorders | 5 | 2021 | 766 | 0.710 |
Why?
|
| Male | 64 | 2025 | 27578 | 0.700 |
Why?
|
| Female | 68 | 2025 | 30924 | 0.690 |
Why?
|
| Humans | 93 | 2025 | 59526 | 0.680 |
Why?
|
| Polymorphism, Genetic | 4 | 2011 | 197 | 0.650 |
Why?
|
| Polymorphism, Single Nucleotide | 15 | 2022 | 454 | 0.640 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 5 | 2010 | 24 | 0.590 |
Why?
|
| Genotype | 15 | 2014 | 642 | 0.570 |
Why?
|
| RNA, Small Interfering | 3 | 2017 | 851 | 0.530 |
Why?
|
| Blood Platelets | 5 | 2016 | 180 | 0.520 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 1023 | 0.510 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 6 | 2008 | 17 | 0.510 |
Why?
|
| Coronary Disease | 1 | 2017 | 250 | 0.500 |
Why?
|
| Age Factors | 12 | 2021 | 1518 | 0.490 |
Why?
|
| Brain-Derived Neurotrophic Factor | 3 | 2010 | 35 | 0.480 |
Why?
|
| Massachusetts | 9 | 2025 | 2089 | 0.460 |
Why?
|
| Genetic Markers | 3 | 2009 | 121 | 0.450 |
Why?
|
| Temperament | 1 | 2014 | 18 | 0.450 |
Why?
|
| Anger | 1 | 2014 | 23 | 0.450 |
Why?
|
| Blood Pressure | 3 | 2012 | 522 | 0.450 |
Why?
|
| Adult | 33 | 2025 | 15791 | 0.450 |
Why?
|
| Conduct Disorder | 5 | 2009 | 23 | 0.440 |
Why?
|
| Aging | 2 | 2012 | 723 | 0.440 |
Why?
|
| United States | 11 | 2025 | 7514 | 0.440 |
Why?
|
| Irritable Mood | 3 | 2014 | 15 | 0.420 |
Why?
|
| Middle Aged | 24 | 2025 | 16279 | 0.410 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2009 | 6 | 0.410 |
Why?
|
| Young Adult | 15 | 2025 | 4332 | 0.400 |
Why?
|
| RNA, Viral | 3 | 2019 | 266 | 0.400 |
Why?
|
| Molecular Biology | 2 | 2010 | 67 | 0.400 |
Why?
|
| Affective Symptoms | 1 | 2011 | 16 | 0.380 |
Why?
|
| Child, Preschool | 10 | 2025 | 1839 | 0.370 |
Why?
|
| Psychiatric Status Rating Scales | 12 | 2009 | 384 | 0.350 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 7 | 2010 | 123 | 0.350 |
Why?
|
| Mood Disorders | 5 | 2008 | 69 | 0.340 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 2470 | 0.340 |
Why?
|
| Executive Function | 1 | 2010 | 62 | 0.330 |
Why?
|
| Cognition | 4 | 2012 | 459 | 0.330 |
Why?
|
| Family Health | 2 | 2011 | 68 | 0.330 |
Why?
|
| Comorbidity | 15 | 2018 | 1091 | 0.330 |
Why?
|
| Case-Control Studies | 13 | 2011 | 1063 | 0.320 |
Why?
|
| Fee-for-Service Plans | 2 | 2021 | 67 | 0.320 |
Why?
|
| Hypertension | 2 | 2012 | 601 | 0.310 |
Why?
|
| Attention | 1 | 2010 | 153 | 0.310 |
Why?
|
| Neuropsychological Tests | 7 | 2011 | 340 | 0.310 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2008 | 17 | 0.300 |
Why?
|
| Child Behavior Disorders | 4 | 2015 | 42 | 0.300 |
Why?
|
| Stroke | 1 | 2017 | 1139 | 0.300 |
Why?
|
| Aggression | 4 | 2014 | 57 | 0.290 |
Why?
|
| Prevalence | 6 | 2017 | 1281 | 0.280 |
Why?
|
| Social Determinants of Health | 2 | 2021 | 116 | 0.280 |
Why?
|
| Personal Satisfaction | 1 | 2007 | 77 | 0.280 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2015 | 164 | 0.280 |
Why?
|
| Huntington Disease | 2 | 2022 | 146 | 0.280 |
Why?
|
| Genome, Human | 4 | 2016 | 219 | 0.280 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2006 | 22 | 0.280 |
Why?
|
| DNA, Viral | 2 | 2019 | 228 | 0.270 |
Why?
|
| Brain | 5 | 2015 | 1489 | 0.270 |
Why?
|
| Antipsychotic Agents | 4 | 2014 | 312 | 0.270 |
Why?
|
| Age of Onset | 7 | 2010 | 172 | 0.260 |
Why?
|
| Heart Rate | 3 | 2012 | 306 | 0.260 |
Why?
|
| Substance-Related Disorders | 4 | 2021 | 691 | 0.250 |
Why?
|
| Anxiety Disorders | 8 | 2010 | 188 | 0.250 |
Why?
|
| Depressive Disorder, Major | 2 | 2009 | 258 | 0.250 |
Why?
|
| Genetic Association Studies | 5 | 2011 | 118 | 0.230 |
Why?
|
| Aged | 11 | 2021 | 13346 | 0.230 |
Why?
|
| Sex Factors | 5 | 2021 | 960 | 0.220 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 36 | 0.220 |
Why?
|
| Gyrus Cinguli | 3 | 2010 | 57 | 0.210 |
Why?
|
| Psychiatric Department, Hospital | 1 | 2003 | 9 | 0.210 |
Why?
|
| Impulsive Behavior | 1 | 2003 | 28 | 0.210 |
Why?
|
| Health Equity | 1 | 2023 | 42 | 0.200 |
Why?
|
| Genetic Linkage | 4 | 2011 | 101 | 0.200 |
Why?
|
| Frontal Lobe | 3 | 2013 | 66 | 0.200 |
Why?
|
| Smoking | 2 | 2010 | 830 | 0.200 |
Why?
|
| Psychotropic Drugs | 1 | 2003 | 83 | 0.200 |
Why?
|
| Cognition Disorders | 3 | 2009 | 218 | 0.200 |
Why?
|
| Receptors, Dopamine D4 | 3 | 2011 | 7 | 0.190 |
Why?
|
| Surveys and Questionnaires | 3 | 2014 | 2592 | 0.190 |
Why?
|
| Infant, Low Birth Weight | 1 | 2002 | 58 | 0.190 |
Why?
|
| Maternal Behavior | 1 | 2002 | 31 | 0.190 |
Why?
|
| Multimorbidity | 1 | 2021 | 38 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2017 | 250 | 0.180 |
Why?
|
| Attitude to Health | 1 | 2003 | 275 | 0.180 |
Why?
|
| Follow-Up Studies | 8 | 2012 | 2329 | 0.180 |
Why?
|
| HIV Infections | 2 | 2019 | 921 | 0.180 |
Why?
|
| Parietal Lobe | 2 | 2012 | 29 | 0.180 |
Why?
|
| Quality of Life | 1 | 2007 | 1117 | 0.180 |
Why?
|
| Mothers | 1 | 2003 | 261 | 0.170 |
Why?
|
| Pregnancy Complications | 3 | 2015 | 391 | 0.170 |
Why?
|
| Psychopathology | 3 | 2009 | 20 | 0.170 |
Why?
|
| Alcohol Drinking | 1 | 2002 | 299 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 809 | 0.160 |
Why?
|
| Anxiety | 2 | 2014 | 395 | 0.160 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 298 | 0.160 |
Why?
|
| Platelet Aggregation | 2 | 2016 | 59 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2017 | 3101 | 0.150 |
Why?
|
| Cardiovascular Diseases | 3 | 2016 | 827 | 0.150 |
Why?
|
| Antigens, Viral | 1 | 2019 | 131 | 0.150 |
Why?
|
| Gene Expression | 3 | 2013 | 810 | 0.150 |
Why?
|
| DNA Viruses | 1 | 2018 | 15 | 0.150 |
Why?
|
| Herpesviridae | 1 | 2018 | 14 | 0.150 |
Why?
|
| Health Care Reform | 1 | 2019 | 88 | 0.150 |
Why?
|
| HIV Antibodies | 1 | 2019 | 141 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2019 | 2442 | 0.150 |
Why?
|
| Inflammation | 2 | 2015 | 1102 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 328 | 0.150 |
Why?
|
| Obesity | 3 | 2017 | 1186 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2019 | 141 | 0.150 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 155 | 0.150 |
Why?
|
| Hospitalization | 2 | 2014 | 1283 | 0.140 |
Why?
|
| Depression | 3 | 2014 | 857 | 0.140 |
Why?
|
| Minisatellite Repeats | 3 | 2011 | 6 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 224 | 0.140 |
Why?
|
| Biomarkers | 3 | 2017 | 1211 | 0.140 |
Why?
|
| Siblings | 3 | 2011 | 45 | 0.130 |
Why?
|
| C-Reactive Protein | 2 | 2017 | 167 | 0.130 |
Why?
|
| Genetic Variation | 4 | 2012 | 367 | 0.130 |
Why?
|
| Soybean Oil | 1 | 2016 | 31 | 0.130 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2015 | 5 | 0.130 |
Why?
|
| Tryptamines | 1 | 2015 | 12 | 0.130 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 73 | 0.130 |
Why?
|
| Internal-External Control | 1 | 2015 | 32 | 0.130 |
Why?
|
| DNA Copy Number Variations | 2 | 2016 | 65 | 0.130 |
Why?
|
| Phospholipids | 1 | 2016 | 79 | 0.130 |
Why?
|
| Double-Blind Method | 5 | 2010 | 681 | 0.130 |
Why?
|
| Diet, Western | 1 | 2015 | 8 | 0.130 |
Why?
|
| Metabolic Syndrome | 1 | 2017 | 148 | 0.120 |
Why?
|
| Thrombosis | 2 | 2015 | 195 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2006 | 293 | 0.120 |
Why?
|
| Reproducibility of Results | 4 | 2012 | 1551 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 403 | 0.120 |
Why?
|
| Phenotype | 4 | 2017 | 1157 | 0.120 |
Why?
|
| Retrospective Studies | 8 | 2019 | 6011 | 0.120 |
Why?
|
| Pregnancy, High-Risk | 1 | 2014 | 22 | 0.120 |
Why?
|
| HIV-1 | 2 | 2019 | 708 | 0.120 |
Why?
|
| Virus Replication | 1 | 2016 | 304 | 0.120 |
Why?
|
| Atrial Fibrillation | 2 | 2012 | 798 | 0.120 |
Why?
|
| Longitudinal Studies | 6 | 2016 | 1225 | 0.110 |
Why?
|
| Peripartum Period | 1 | 2014 | 31 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2014 | 7 | 0.110 |
Why?
|
| Cardiovirus Infections | 1 | 2014 | 13 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2014 | 16 | 0.110 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2014 | 9 | 0.110 |
Why?
|
| Encephalomyocarditis virus | 1 | 2014 | 14 | 0.110 |
Why?
|
| Quinolones | 1 | 2014 | 27 | 0.110 |
Why?
|
| Hostility | 1 | 2014 | 17 | 0.110 |
Why?
|
| Megakaryocytes | 1 | 2014 | 20 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2013 | 2040 | 0.110 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2014 | 52 | 0.110 |
Why?
|
| Piperazines | 1 | 2014 | 93 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 1238 | 0.110 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2014 | 97 | 0.110 |
Why?
|
| Insulin Resistance | 1 | 2017 | 404 | 0.110 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 847 | 0.110 |
Why?
|
| Functional Neuroimaging | 1 | 2013 | 15 | 0.110 |
Why?
|
| Pregnancy | 5 | 2015 | 2355 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2017 | 519 | 0.110 |
Why?
|
| Platelet Activation | 1 | 2014 | 89 | 0.110 |
Why?
|
| Propylamines | 1 | 2012 | 8 | 0.110 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2012 | 14 | 0.100 |
Why?
|
| Toll-Like Receptors | 1 | 2015 | 434 | 0.100 |
Why?
|
| Photoplethysmography | 1 | 2012 | 33 | 0.100 |
Why?
|
| Calcium Signaling | 1 | 2014 | 153 | 0.100 |
Why?
|
| Receptors, Metabotropic Glutamate | 2 | 2011 | 30 | 0.100 |
Why?
|
| Alleles | 4 | 2022 | 424 | 0.100 |
Why?
|
| Tachycardia | 1 | 2012 | 27 | 0.100 |
Why?
|
| Cell Phone | 1 | 2012 | 43 | 0.100 |
Why?
|
| Postpartum Period | 1 | 2014 | 203 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 265 | 0.100 |
Why?
|
| Child of Impaired Parents | 2 | 2009 | 28 | 0.100 |
Why?
|
| Family | 3 | 2009 | 220 | 0.100 |
Why?
|
| Inheritance Patterns | 1 | 2012 | 18 | 0.100 |
Why?
|
| Echocardiography, Doppler | 1 | 2012 | 131 | 0.100 |
Why?
|
| Gene Dosage | 1 | 2012 | 60 | 0.100 |
Why?
|
| Electric Countershock | 1 | 2012 | 98 | 0.100 |
Why?
|
| Nerve Net | 1 | 2012 | 94 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2013 | 309 | 0.100 |
Why?
|
| Genetics | 1 | 2011 | 13 | 0.100 |
Why?
|
| Intelligence | 1 | 2012 | 56 | 0.100 |
Why?
|
| Probability | 2 | 2008 | 172 | 0.100 |
Why?
|
| Semaphorin-3A | 1 | 2011 | 4 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 926 | 0.100 |
Why?
|
| Sialoglycoproteins | 1 | 2011 | 20 | 0.100 |
Why?
|
| Diseases in Twins | 2 | 2010 | 54 | 0.090 |
Why?
|
| Inpatients | 1 | 2014 | 296 | 0.090 |
Why?
|
| Receptors, Nicotinic | 1 | 2012 | 67 | 0.090 |
Why?
|
| Psychological Tests | 1 | 2011 | 50 | 0.090 |
Why?
|
| Homeostasis | 1 | 2014 | 342 | 0.090 |
Why?
|
| Risk Factors | 7 | 2023 | 5017 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 50 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 673 | 0.090 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 66 | 0.090 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2010 | 2 | 0.090 |
Why?
|
| Memory Disorders | 1 | 2011 | 45 | 0.090 |
Why?
|
| California | 1 | 2011 | 160 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 27 | 0.090 |
Why?
|
| Osmosis | 1 | 2010 | 5 | 0.090 |
Why?
|
| Memory, Short-Term | 1 | 2011 | 59 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 669 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 139 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2010 | 115 | 0.090 |
Why?
|
| Personality Assessment | 1 | 2010 | 21 | 0.090 |
Why?
|
| Valine | 1 | 2010 | 30 | 0.090 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 2 | 1 | 2009 | 1 | 0.090 |
Why?
|
| Methionine | 1 | 2010 | 56 | 0.090 |
Why?
|
| Risk | 3 | 2010 | 372 | 0.090 |
Why?
|
| Twins | 1 | 2010 | 52 | 0.080 |
Why?
|
| CLOCK Proteins | 1 | 2009 | 45 | 0.080 |
Why?
|
| Treatment Outcome | 7 | 2016 | 5183 | 0.080 |
Why?
|
| Glutamine | 2 | 2006 | 47 | 0.080 |
Why?
|
| Glutamate Decarboxylase | 1 | 2009 | 23 | 0.080 |
Why?
|
| Glutamic Acid | 2 | 2006 | 98 | 0.080 |
Why?
|
| Nuclear Family | 1 | 2009 | 19 | 0.080 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2008 | 2 | 0.080 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2008 | 9 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 387 | 0.080 |
Why?
|
| Immunity, Innate | 1 | 2015 | 766 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2008 | 23 | 0.080 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2008 | 27 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 116 | 0.080 |
Why?
|
| Adoption | 1 | 2008 | 2 | 0.080 |
Why?
|
| 3' Untranslated Regions | 1 | 2008 | 84 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2010 | 258 | 0.080 |
Why?
|
| Mice | 6 | 2022 | 10280 | 0.070 |
Why?
|
| Wechsler Scales | 1 | 2007 | 17 | 0.070 |
Why?
|
| Social Adjustment | 1 | 2007 | 34 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 291 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2010 | 455 | 0.070 |
Why?
|
| Tandem Repeat Sequences | 1 | 2006 | 28 | 0.070 |
Why?
|
| Microsatellite Repeats | 1 | 2006 | 37 | 0.070 |
Why?
|
| Risperidone | 1 | 2006 | 25 | 0.070 |
Why?
|
| Haplotypes | 3 | 2012 | 116 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2014 | 2891 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2008 | 484 | 0.070 |
Why?
|
| Psychophysiologic Disorders | 1 | 2006 | 7 | 0.070 |
Why?
|
| Disease Models, Animal | 4 | 2015 | 2069 | 0.070 |
Why?
|
| DNA Primers | 1 | 2006 | 291 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2019 | 1311 | 0.070 |
Why?
|
| Educational Status | 1 | 2007 | 271 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2006 | 80 | 0.060 |
Why?
|
| Marijuana Abuse | 1 | 2005 | 20 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2011 | 842 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2006 | 77 | 0.060 |
Why?
|
| Anti-Anxiety Agents | 1 | 2005 | 31 | 0.060 |
Why?
|
| Fluoxetine | 1 | 2005 | 44 | 0.060 |
Why?
|
| Substance Abuse Detection | 1 | 2005 | 39 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 2007 | 264 | 0.060 |
Why?
|
| Psychometrics | 2 | 2006 | 356 | 0.060 |
Why?
|
| Porphyromonas gingivalis | 2 | 2015 | 16 | 0.060 |
Why?
|
| DNA | 1 | 2008 | 794 | 0.060 |
Why?
|
| Remission Induction | 1 | 2004 | 137 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2009 | 1915 | 0.060 |
Why?
|
| Psychological Theory | 1 | 2003 | 26 | 0.060 |
Why?
|
| Norway | 2 | 2015 | 19 | 0.050 |
Why?
|
| Animals | 6 | 2022 | 19663 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2004 | 155 | 0.050 |
Why?
|
| Interview, Psychological | 1 | 2003 | 77 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 254 | 0.050 |
Why?
|
| Atherosclerosis | 2 | 2015 | 147 | 0.050 |
Why?
|
| Infant | 2 | 2019 | 1527 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2023 | 91 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 699 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2003 | 256 | 0.050 |
Why?
|
| Neutrophils | 2 | 2015 | 357 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1095 | 0.050 |
Why?
|
| Obstetric Labor, Premature | 1 | 2002 | 33 | 0.050 |
Why?
|
| Schools | 1 | 2003 | 156 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 673 | 0.050 |
Why?
|
| Huntingtin Protein | 1 | 2022 | 138 | 0.050 |
Why?
|
| Time Factors | 4 | 2010 | 3579 | 0.040 |
Why?
|
| Cerebellum | 2 | 2013 | 94 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 900 | 0.040 |
Why?
|
| Europe | 2 | 2011 | 183 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 781 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2016 | 1470 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2010 | 1449 | 0.040 |
Why?
|
| Models, Neurological | 2 | 2010 | 81 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2019 | 10 | 0.040 |
Why?
|
| Prefrontal Cortex | 2 | 2011 | 113 | 0.040 |
Why?
|
| Delayed-Action Preparations | 2 | 2010 | 105 | 0.040 |
Why?
|
| Lod Score | 2 | 2008 | 26 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2019 | 80 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2014 | 1989 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2018 | 46 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 22 | 0.040 |
Why?
|
| Disease Progression | 1 | 2003 | 1044 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 227 | 0.040 |
Why?
|
| Motivation | 1 | 2020 | 266 | 0.040 |
Why?
|
| Dopamine | 2 | 2011 | 102 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2010 | 344 | 0.040 |
Why?
|
| Prognosis | 2 | 2015 | 1572 | 0.040 |
Why?
|
| Antisocial Personality Disorder | 2 | 2009 | 35 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 452 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2017 | 53 | 0.030 |
Why?
|
| Demography | 2 | 2008 | 178 | 0.030 |
Why?
|
| Creatine | 2 | 2006 | 26 | 0.030 |
Why?
|
| Adiposity | 1 | 2017 | 79 | 0.030 |
Why?
|
| Medicare | 1 | 2020 | 601 | 0.030 |
Why?
|
| Plasma | 1 | 2016 | 33 | 0.030 |
Why?
|
| Research Design | 2 | 2010 | 566 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 94 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 72 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 59 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2017 | 201 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2016 | 170 | 0.030 |
Why?
|
| Cholesterol | 1 | 2017 | 255 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 192 | 0.030 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2015 | 21 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 101 | 0.030 |
Why?
|
| Triglycerides | 1 | 2017 | 242 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 229 | 0.030 |
Why?
|
| Migraine Disorders | 1 | 2015 | 45 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 238 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2008 | 486 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 838 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2015 | 99 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 160 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 247 | 0.030 |
Why?
|
| Aripiprazole | 1 | 2014 | 6 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 2014 | 20 | 0.030 |
Why?
|
| Secretory Vesicles | 1 | 2014 | 22 | 0.030 |
Why?
|
| Platelet Count | 1 | 2014 | 33 | 0.030 |
Why?
|
| Bacteroidaceae Infections | 1 | 2014 | 3 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2015 | 120 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2015 | 209 | 0.030 |
Why?
|
| Platelet Adhesiveness | 1 | 2014 | 13 | 0.030 |
Why?
|
| Thrombin | 1 | 2014 | 34 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 169 | 0.030 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2014 | 143 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 526 | 0.030 |
Why?
|
| Imidazoles | 1 | 2014 | 83 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 121 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 125 | 0.030 |
Why?
|
| Basal Ganglia | 1 | 2013 | 30 | 0.030 |
Why?
|
| Pyridines | 1 | 2014 | 98 | 0.030 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2012 | 6 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2014 | 204 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 886 | 0.030 |
Why?
|
| Insulin | 1 | 2017 | 687 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 185 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2013 | 99 | 0.030 |
Why?
|
| Emulsions | 1 | 2016 | 450 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 201 | 0.030 |
Why?
|
| Segmental Duplications, Genomic | 1 | 2012 | 1 | 0.020 |
Why?
|
| PAX5 Transcription Factor | 1 | 2012 | 12 | 0.020 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2012 | 7 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 255 | 0.020 |
Why?
|
| Aptitude | 1 | 2012 | 10 | 0.020 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Heart Atria | 1 | 2012 | 138 | 0.020 |
Why?
|
| Causality | 1 | 2012 | 56 | 0.020 |
Why?
|
| United Kingdom | 1 | 2012 | 69 | 0.020 |
Why?
|
| Receptors, Peptide | 1 | 2011 | 32 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 378 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2014 | 461 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 145 | 0.020 |
Why?
|
| Equipment Design | 1 | 2012 | 317 | 0.020 |
Why?
|
| Cadherins | 1 | 2011 | 67 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 155 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 861 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 1221 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 578 | 0.020 |
Why?
|
| Cytokines | 1 | 2015 | 906 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 127 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 771 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 298 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2011 | 130 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2011 | 132 | 0.020 |
Why?
|
| Spain | 1 | 2010 | 27 | 0.020 |
Why?
|
| Netherlands | 1 | 2010 | 24 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2010 | 41 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Germany | 1 | 2010 | 52 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2011 | 230 | 0.020 |
Why?
|
| RNA | 1 | 2013 | 404 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 576 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 1032 | 0.020 |
Why?
|
| Lithium Compounds | 1 | 2009 | 9 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT1B | 1 | 2009 | 1 | 0.020 |
Why?
|
| Receptors, Dopamine D5 | 1 | 2009 | 2 | 0.020 |
Why?
|
| Oxygen | 1 | 2011 | 308 | 0.020 |
Why?
|
| Cell Line | 1 | 2014 | 2015 | 0.020 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 321 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 921 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1538 | 0.020 |
Why?
|
| Introns | 1 | 2009 | 106 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2009 | 129 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2009 | 304 | 0.020 |
Why?
|
| Systole | 1 | 2009 | 109 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2008 | 22 | 0.020 |
Why?
|
| Diastole | 1 | 2009 | 89 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2008 | 26 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2010 | 253 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2009 | 95 | 0.020 |
Why?
|
| Social Environment | 1 | 2009 | 95 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2009 | 133 | 0.020 |
Why?
|
| Heterozygote | 1 | 2008 | 168 | 0.020 |
Why?
|
| Outpatients | 1 | 2008 | 131 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2008 | 294 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 636 | 0.020 |
Why?
|
| Reaction Time | 1 | 2008 | 119 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 990 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 422 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2008 | 125 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2010 | 293 | 0.020 |
Why?
|
| Enuresis | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiography | 1 | 2008 | 506 | 0.020 |
Why?
|
| Genome | 1 | 2009 | 253 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1252 | 0.020 |
Why?
|
| Inositol | 1 | 2006 | 10 | 0.020 |
Why?
|
| Phosphocreatine | 1 | 2006 | 24 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2009 | 524 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2006 | 147 | 0.020 |
Why?
|
| Movement Disorders | 1 | 2006 | 23 | 0.020 |
Why?
|
| Protons | 1 | 2006 | 61 | 0.020 |
Why?
|
| Serotonin | 1 | 2006 | 66 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 283 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2005 | 133 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 72 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2005 | 97 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2005 | 98 | 0.020 |
Why?
|
| Social Behavior | 1 | 2005 | 88 | 0.010 |
Why?
|
| Parents | 1 | 2005 | 380 | 0.010 |
Why?
|